Neurol. praxi. 2016;17(6):407-411 | DOI: 10.36290/neu.2016.085

Escalation therapy in multiple sclerosis

MUDr. Zbyšek Pavelek1, MUDr. Pavel Ryška, Ph.D.2, doc. MUDr. Martin Vališ, Ph.D.1
1 Neurologická klinika LF a FN Hradec Králové
2 Radiologická klinika LF a FN Hradec Králové

Multiple sclerosis is a chronic inflammatory demyelinating disease which affect central nervous system with neurodegenerative changes of brain. This autoimmune disease manifests itself with various symptoms. Treatment options in multiple sclerosis have expanded considerably in the recent years. This review explore current treatment options for multiple sclerosis. We report one casee from our own patients base through we demonstrate possible use of fingolimod for treatment escalation.

Keywords: multiple sclerosis, escalation therapy, NEDA

Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pavelek Z, Ryška P, Vališ M. Escalation therapy in multiple sclerosis. Neurol. praxi. 2016;17(6):407-411. doi: 10.36290/neu.2016.085.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010 Mar-Apr; 33(2): 91-101. Go to original source... Go to PubMed...
    2. Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012; 11(1): 33-41. Go to original source... Go to PubMed...
    3. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Ferna?ndez O, Hartung HP, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR, and the Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582. Go to original source... Go to PubMed...
    4. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 374(9700): 1503-1511. Go to original source... Go to PubMed...
    5. Cree BAC, Kappos L, Freedman MS, Cohen JA, Sprenger T, Ritter S, Tomic D, Piani Weber D. Long-term effects of fingolimod on NEDA by year of treatment. Poster presented at: 31st ECTRIMS Annual Congress; October 7-10, 2015; Barcelona, Spain. Poster Session 1; P627.
    6. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009 Jun 9; 106(23): 9362-9367. Go to original source... Go to PubMed...
    7. Holick FM. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80: 1678S-1688S. Go to original source... Go to PubMed...
    8. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R; for the BENEFIT Study Group. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249. Go to original source... Go to PubMed...
    9. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011 Jun; 10(6): 520-529. Go to original source... Go to PubMed...
    10. Loma I, Heyman R. Multiple Sclerosis: Pathogenesis and Treatment. Curr Neuropharmacol. 2011 Sep; 9(3): 409-416. Go to original source... Go to PubMed...
    11. Matesanz F, González-Pérez A, Lucas M, Sanna S, Gayán J, Urcelay E, Zara I, Pitzalis M, Cavanillas ML, Arroyo R, Zoledziewska M, Marrosu M, Fernández O, Leyva L, Alcina A, Fedetz M, Moreno-Rey C, Velasco J, Real LM, Ruiz-Pe?a JL, Cucca F, Ruiz A, Izquierdo G. Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1. PLoS One. 2012; 7(5): e36140. Go to original source... Go to PubMed...
    12. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1): 121-127. Go to original source... Go to PubMed...
    13. Miller JR. The importace of early diagnosis of multiple sclerosis, J Manag Care Pharm 2004; 10: S4-S11.
    14. Pavelek Z, Krejsek J, Vališ M. Role T a B lymfocytů v patogenezi roztroušené sklerózy. Neurol. praxi, 2016; 17(2): 100-103. Go to original source...
    15. Pohl D, Krone K, Rostasy K, Kahler E, Brunner E, Lehnert M, Wagner HJ, Gärtner J, Hanefeld F. High Seroprevalence of Epstein-Barr Virus in Children with Multiple Sclerosis. Neurology 2006; 67: 2063-2065. Go to original source... Go to PubMed...
    16. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O ?Connor P, Sandberg-Wolheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. ANN NEUROL 2011; 69: 292-302. Go to original source... Go to PubMed...
    17. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005; 58(6): 840-846. Go to original source... Go to PubMed...
    18. Salzer J, Hallmans G, Nyström M, Stenlund H, Wadell G, Sundström P. Vitamin D as a protective factor in multiple sclerosis. Neurology. 2012 Nov 20; 79(21): 2140-2145. Go to original source... Go to PubMed...
    19. Trojano M, Liguori M, Paolicelli D, Zimatore GB, De Robertis F, Avolio C, Giuliani F, Fuiani A, Livrea P; Southern Italy MS Group. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler. 2003; 9: 451-457. Go to original source... Go to PubMed...
    20. Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S, Renoux C, Confavreux C. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology. 2003; 61: 184-189. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.